Advertisement
Advertisement

OPK

OPK logo

Opko Health Inc.

1.51
USD
Sponsored
+0.02
+1.34%
Aug 26, 15:56 UTC -4
Closed
exchange

After-Market

1.50

-0.01
-0.99%

Opko Health Inc. Profile

About

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.

Info & Links

CEO

Phillip Frost

Headquarters

4400 BISCAYNE BLVD.
MIAMI, FL 33137, UNITED STATES

Industry

Medical Instruments

Sector

Medical

Website

www.opko.com

Auditor

Ernst & Young LLP

Share holders

334

Employees

1,373

Opko Health Inc. Statistics

Valuation Measures

Market Capitalization2

1.12B

Enterprise Value

1.16B

Enterprise Value/EBITDA(ttm)

27.66

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.88

Price to Book(mrq)

0.93

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

40.45%

Operating Margin(ttm)

-12.40%

Profit Margin(ttm)

-14.03%

Return on Equity(ttm)

-5.88%

Return on Invested Capital(ttm)

-4.75%

Return on Assets(ttm)

-3.83%

Income Statement

Revenue(ttm)

587.90M

Revenue Per Share(ttm)

0.79

Gross Profit(ttm)

239.69M

EBITDA(ttm)3

42.02M

Net Income Available to Common(ttm)

-72.89M

Diluted EPS(ttm)

-0.09

Share Statistics

Beta (5Y Monthly)

1.51

52-Week Change

8.63%

S&P 500 52-Week Change

19.02%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

746.33M

Dividend Yield

0.00%

Float4

412.57M

% Held by Insiders

44.72%

% Held by Institutions

64.63%

Balance Sheet

Total Cash(mrq)

300.76M

Total Cash Per Share(mrq)

0.40

Total Debt(mrq)

347.27M

Total Debt/Equity(mrq)

29.33%

Current Ratio(mrq)

3.35%

Quick Ratio(mrq)

2.93%

Book Value Per Share(mrq)

1.59

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.08

Free Cash Flow(ytd)

-67.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement